Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program.

doi:10.1186/s12885-016-2440-9

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program.

BMC cancer - 7 Jul 2016

Adenis Antoine, de la Fouchardiere Christelle, Paule Bernard, Burtin Pascal, Tougeron David, Wallet Jennifer, Dourthe Louis-Marie, Etienne Pierre-Luc, Mineur Laurent, Clisant Stéphanie, Phelip Jean-Marc, Kramar Andrew, Andre Thierry

Abstract excerpt

BACKGROUND: Randomized trials have shown a survival benefit for regorafenib over placebo in patients with metastatic colorectal cancer (mCRC) that progressed after standard therapies. We evaluated survival and safety outcomes in patients treated with regorafenib in a real-life setting. METHODS: REBECCA is a cohort study nested within a compassionate use program designed to evaluate survival, safety, and potential...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colorectal Neoplasms

Share to Kaplan-Meier Estimate

Share to Neoplasm Metastasis

Share to Phenylurea Compounds

Share to Proto-Oncogene Proteins p21(ras)

Share to Pyridines

Share to Survival Analysis

Source

Open in PubMed Open full text

Identifiers

PMID: 27389564
DOI: 10.1186/s12885-016-2440-9
PMCID: PMC4936193

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program.PMID 27389564Read ↗

Regorafenib Therapy as a Third-Line Treatment for Metastatic Colorectal Cancer: A Single Center Long Term ExperienceSemantic proximity Read ↗

Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer.Semantic proximity Read ↗

Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).Semantic proximity Read ↗

Treatment of patients with BRAFV600E-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset.Semantic proximity Read ↗

Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumabSemantic proximity Read ↗

First-line treatment efficacy and prognostic model in RAS-mutant metastatic colorectal cancer: a real-world study.Semantic proximity Read ↗

Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC.Semantic proximity Read ↗

Clinical and molecular assessment of regorafenib monotherapy.Semantic proximity Read ↗

Retrospective Analysis of Treatment Pathways in Patients With BRAFV600E-mutant Metastatic Colorectal Carcinoma - MORSECRC.Semantic proximity Read ↗

Regorafenib in Bone Sarcoma: A Systematic Review and Meta-Analysis of Its Effectiveness and Safety in Cancer TreatmentSemantic proximity Read ↗

Impact of encorafenib on survival of patients with BRAFV600E-mutant metastatic colorectal cancer in a real-world setting.Semantic proximity Read ↗

[Regorafenib in patients with metastatic colorectal cancer: a review and an update].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.